NasdaqGM:ZLABBiotechs
A Look At Zai Lab (ZLAB) Valuation After New Amgen Oncology Collaboration News
Zai Lab (NasdaqGM:ZLAB) is back on investors’ radar after announcing a global clinical trial collaboration with Amgen to test their DLL3-targeting therapies in patients with extensive-stage small cell lung cancer.
See our latest analysis for Zai Lab.
The Amgen tie-up has arrived during a period of stronger short term momentum for Zai Lab, with a 7 day share price return of 13.39% and a 90 day share price return of 12.82%. However, the 1 year total shareholder return decline of 35.76% shows...